Filing Details
- Accession Number:
- 0001415889-24-012937
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-10 21:35:17
- Reporting Period:
- 2024-05-10
- Accepted Time:
- 2024-05-10 21:35:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1604821 | Natera Inc. | NTRA | Services-Medical Laboratories (8071) | 010894487 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1857843 | Daniel Rabinowitz | C/O Natera, Inc. 13011 Mccallen Pass Building A Suite 100 Austin TX 78753 | Sec. And Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-05-10 | 30,000 | $19.68 | 234,495 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-05-10 | 5,997 | $101.55 | 228,498 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-10 | 9,398 | $102.91 | 219,100 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-10 | 4,255 | $104.03 | 214,845 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-10 | 10,350 | $108.10 | 204,495 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-05-10 | 30,000 | $0.00 | 30,000 | $19.68 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 12,500 | 2029-03-21 | No | 4 | M | Direct |
Footnotes
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2023.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.30 to $102.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.83 to $103.55 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.85 to $104.77 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.55 to $108.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option shares are fully exercisable.
Billionaire Hedge Funds
